MaxCyte (NASDAQ:MXCT) Issues Earnings Results

Key Points

• MaxCyte slightly beat earnings expectations, reporting an adjusted loss of $0.08 per share versus the expected $0.09 loss, while quarterly revenue of $6.5 million was broadly in line with estimates.
• Management reiterated 2026 revenue guidance of $30 million–$32 million, expecting instrument placements to recover and become the primary growth driver in the second half.
• Despite partnerships with Genentech and continued CASGEVY momentum, second-quarter revenue fell 15% year over year to $7.3 million, core revenue declined 21%, and gross margin dropped to 77%.

MaxCyte (NASDAQ:MXCT - Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($0.08) EPS for the quarter, topping analysts' consensus estimates of ($0.09) by $0.01, FiscalAI reports. MaxCyte had a negative return on equity of 20.03% and a negative net margin of 121.16%.The firm had revenue of $6.50 million during the quarter, compared to analyst estimates of $6.51 million.

Here are the key takeaways from MaxCyte's conference call:

• MaxCyte reiterated its 2026 revenue guidance of $30 million–$32 million, with low single-digit year-over-year growth expected in the second half as instrument placements recover and prior inventory and partner-program headwinds subside.
• The new enterprise-level Genentech partnership provides access to MaxCyte’s ExPERT GTx, electroporation, and SeQure technologies across multiple programs and development stages, potentially creating recurring license, platform-use, instrument, consumables, and milestone revenue.
• Commercial momentum for Vertex’s CASGEVY continued, with approximately $76 million in second-quarter sales and more than 100 patient treatment initiations; MaxCyte’s SPL-related revenue rose to $0.8 million from $0.3 million a year earlier.
• Management reported broad stabilization in instrument and processing-assembly demand, early traction for the DTx platform, and expects instrument revenue to be the primary growth driver in the second half; it also sees potential commercial launches from five partner programs over the next few years, mainly in 2027.
• Second-quarter revenue declined 15% year over year to $7.3 million, while core revenue fell 21%; gross margin also decreased to 77% from 82% and is expected to remain in the mid-70% range as instrument revenue represents a larger mix.

MaxCyte Trading Up 2.4%

Shares of NASDAQ MXCT traded up $0.03 during midday trading on Wednesday, hitting $1.27. The company's stock had a trading volume of 1,896,727 shares, compared to its average volume of 1,105,043. The firm has a market capitalization of $136.04 million, a price-to-earnings ratio of -3.43 and a beta of 1.48. The stock has a fifty day moving average price of $1.19 and a 200 day moving average price of $0.98. MaxCyte has a one year low of $0.64 and a one year high of $1.86.

Wall Street Analyst Weigh In

Several research firms have weighed in on MXCT. Wall Street Zen raised MaxCyte from a "sell" rating to a "hold" rating in a research report on Saturday, May 16th. Weiss Ratings raised MaxCyte from a "sell (e+)" rating to a "sell (d-)" rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average price target of $5.00.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of MXCT. AQR Capital Management LLC lifted its stake in MaxCyte by 227.3% in the 1st quarter. AQR Capital Management LLC now owns 95,501 shares of the company's stock worth $261,000 after purchasing an additional 66,323 shares in the last quarter. American Century Companies Inc. raised its stake in MaxCyte by 10.6% in the second quarter. American Century Companies Inc. now owns 196,686 shares of the company's stock valued at $429,000 after purchasing an additional 18,848 shares in the last quarter. Prudential Financial Inc. bought a new stake in MaxCyte during the second quarter valued at approximately $26,000. Hsbc Holdings PLC lifted its position in MaxCyte by 410.2% during the second quarter. Hsbc Holdings PLC now owns 273,218 shares of the company's stock valued at $598,000 after purchasing an additional 219,662 shares during the last quarter. Finally, Marshall Wace LLP purchased a new position in MaxCyte in the 2nd quarter worth approximately $282,000. 68.81% of the stock is currently owned by hedge funds and other institutional investors.

MaxCyte Company Profile

MaxCyte, Inc NASDAQ: MXCT is a clinical‐stage cell therapy platform company that develops and commercializes proprietary flow electroporation technology for the delivery of macromolecules into living cells. The company's instruments and consumables are designed to support research, preclinical development and clinical‐scale manufacturing of cell therapies across a variety of modalities, including engineered T cells, natural killer (NK) cells and induced pluripotent stem cell (iPSC) therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source